Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Donald Graham

Internal Medicine Springfield, IL Medical Doctor

NPI 1508962366 CMS profile 947157

301 N 8Th St, Springfield, IL 62701

Open in the dashboard

General payments

$14,988

36 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,528 paid to institutions, not to them · program year 2019

Through program year 2019, Donald Graham of Springfield, IL is reported in the CMS Open Payments database as having received $14,988 across 36 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12,528 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $14,988 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Graham
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Donald Graham were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Donald Graham Internal Medicine median Middle half National median
2019 $14,988 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program year 2019
  1. Insmed, Inc. $9,916 17 payments
  2. Astellas Pharma US Inc $4,886 11 payments
  3. Janssen Biotech, Inc. $118 7 payments
  4. W. L. Gore & Associates, Inc. $68 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,920 2 payments
  2. Consulting Fee $4,030 1 payment
  3. Travel and Lodging $2,250 13 payments
  4. Food and Beverage $788 20 payments
Products named General payments · program year 2019
  1. Arikayce $9,916 17 payments
  2. CRESEMBA $4,886 11 payments
  3. SYMTUZA $118 7 payments
  4. EXCLUDER Iliac Branch Endoprosthesis $68 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

660

Median for Internal Medicine: 777

Drug cost

$331,097

Median for Internal Medicine: $73,373

Branded share of claims

23.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 29 $132,606
Juluca Dolutegravir/Rilpivirine Brand 15 $79,289
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 17 $67,165
Prezcobix Darunavir/Cobicistat Brand 11 $31,513
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 26 $8,189
Trimethoprim Generic 63 $4,976
Ceftriaxone Ceftriaxone Sodium Brand 19 $1,279
Ethambutol Hcl Generic 12 $940
Doxycycline Monohydrate Generic 30 $698
Potassium Chloride Generic 20 $581

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$71,319

Of which drugs: $24,900

Medicare patients

104

Average age 75

Services billed

1,639

55 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 37%
Diabetes 33%
COPD 33%
Heart failure 32%
Chronic kidney disease 30%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 27 27 $7,576
Vaccine for influenza for injection into muscle 90653 Office 31 31 $2,496

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record